Many studies have found increased serum or plasma levels of soluble CD40L (sCD40L) in patients suffering from systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), inflammatory bowel disease (IBD), and cardiovascular disease (112–117). This evidence concerns the gene CD40LG and synovial sarcoma.